DeepMed Research

ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms

Phase 4

Completed

Conditions: Cataract
Dry Eye Syndromes

Interventions: Drug: Sodium Carboxymethylcellulose
Drug: Levofloxacin
Drug: Prednisolone

First Posted Date: 2014-01-07

Last Posted Date: 2014-04-23

Lead Sponsor: Allergan

Target Recruit Count: 180

Registration Number: NCT02028754

A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: 0.03% Bimatoprost

First Posted Date: 2013-12-25

Last Posted Date: 2014-07-21

Lead Sponsor: Allergan

Target Recruit Count: 87

Registration Number: NCT02020512

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

Phase 2

Terminated

Conditions: Dry Eye Syndromes

Interventions: Drug: Vehicle
Drug: Cyclosporine New Ophthalmic Formulation
Other: Sham

First Posted Date: 2013-12-17

Last Posted Date: 2018-05-15

Lead Sponsor: Allergan

Target Recruit Count: 55

Registration Number: NCT02013791

Locations: 🇺🇸
Wolstan & Goldberg Eye Associates, Torrance, California, United States
🇺🇸
Johns Hopkins University - Wilmer Eye Institute, Baltimore, Maryland, United States
🇺🇸
Lugene Eye Institute, Glendale, California, United States

and more 5 locations

Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea

Completed

Conditions: Urinary Incontinence
Urinary Bladder, Overactive

Interventions: Biological: botulinum toxin Type A

First Posted Date: 2013-12-13

Last Posted Date: 2016-09-22

Lead Sponsor: Allergan

Target Recruit Count: 523

Registration Number: NCT02010788

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy

Phase 2

Completed

Conditions: Masseter Muscle Hypertrophy

Interventions: Biological: botulinum toxin Type A
Drug: Normal saline

First Posted Date: 2013-12-13

Last Posted Date: 2019-05-28

Lead Sponsor: Allergan

Target Recruit Count: 187

Registration Number: NCT02010775

Locations: 🇦🇺
Central Sydney Dermatology, Sydney, New South Wales, Australia
🇦🇺
The Rose Medical & Aesthetic Centre, North Fremantle, Western Australia, Australia
🇨🇦
Dr. Shannon Humphrey Inc., Vancouver, British Columbia, Canada

and more 11 locations

A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension

Phase 4

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: 0.15% Brimonidine Tartrate

First Posted Date: 2013-12-06

Last Posted Date: 2014-07-22

Lead Sponsor: Allergan

Target Recruit Count: 376

Registration Number: NCT02003534

A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting

Completed

Conditions: Ocular Hypertension
Glaucoma, Primary Open Angle

Interventions: Drug: Fixed Combination Bimatoprost and Timolol

First Posted Date: 2013-12-03

Last Posted Date: 2019-04-19

Lead Sponsor: Allergan

Target Recruit Count: 1553

Registration Number: NCT01999348

A Safety and Effectiveness Study of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement

Not Applicable

Completed

Conditions: Subjects Desiring Lip Augmentation

Interventions: Device: JUVEDERM VOLBELLA® XC
Device: Restylane-L®

First Posted Date: 2013-12-02

Last Posted Date: 2019-04-26

Lead Sponsor: Allergan

Target Recruit Count: 225

Registration Number: NCT01998581

Safety and Efficacy of Combigan® Ophthalmic Solution in Korea

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: brimonidine tartrate/timolol maleate Ophthalmic Solution

First Posted Date: 2013-11-19

Last Posted Date: 2014-04-04

Lead Sponsor: Allergan

Target Recruit Count: 732

Registration Number: NCT01987752

Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

Completed

Conditions: Conjunctivitis, Allergic

Interventions: Drug: Relestat Ophthalmic Solution 0.05%

First Posted Date: 2013-11-19

Last Posted Date: 2014-04-29

Lead Sponsor: Allergan

Target Recruit Count: 847

Registration Number: NCT01987765

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy